Evidence map›Paper›PMID 27118410›Full record

ArticleLeukemia2016

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

M Sobh, M Michallet, G Gahrton, S Iacobelli, A van Biezen, S Schönland, E Petersen, N Schaap, F Bonifazi, L Volin and 15 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 3 pooled it
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Autologous-allogeneicHaematologica · 2024
    Trial
  5. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Prognostic Factors for Postrelapse Survival after ex Vivo CD34Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 20 institutions in 7 countries.

M SobhHematology Department, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
M MichalletHematology Department, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
G GahrtonHematology Department, Karolinska Institutet, Stockholm, Sweden.
S IacobelliCentro Interdipartimentale di Biostatistica e Bioinformatica, Università Tor Vergata, Rome, Italy.
A van BiezenEBMT Data Office, Leiden, The Netherlands.
S SchönlandHematology Department, University of Heidelberg, Heidelberg, Germany.
E PetersenHematology Department, University Medical Center, Utrecht, The Netherlands.
N SchaapHematology department, Radboud University-Nijmegen Medical Center, The Netherlands.
F BonifaziHematology Department, Bologna University, S.Orsola-Malpighi Hospital, Bologna, Italy.
L VolinHematology Department, Helsinki University Central Hospital, Helsinki, Finland.
E MeijerHematology Department, VU University Medical Center, Amsterdam, The Netherlands.
D NiederwieserHematology Department, University Hospital Leipzig, Leipzig, Germany.
J El CheikhHematology Department, Institut Paoli Calmettes, Marseille, France.
R TabriziHematology Department, Hôpital Haut-leveque, Pessac, France.
N FegeuxHematology Department, CHU Lapeyronie, Montpellier, France.
J FinkeHematology Department, University of Freiburg, Freiburg, Germany.
D BunjesHematology Department, Universitätsklinikum Ulm, Ulm, Germany.
J CornelissenHematology Department, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
H EinseleHematology Department, Universitätsklinikum Würzburg, Würzburg, Germany.
B BrunoHematology Department, Presidio Molinette, Torino, Italy.
M PotterHematology Department, Royal Marsden Hospital, London, UK.
R FaninHematology Department, Azienda Ospedaliero Universitaria di Udine, Udine, Italy.
M MohtyHematology Department, Hospital Saint Antoine, Paris, France.
L GarderetHematology Department, Hospital Saint Antoine, Paris, France.
N KrögerHematology Department, University Hospital Eppendorf, Hamburg, Germany.
Hôpital Lyon Sud · FRHôpital Saint-Antoine · FRAmsterdam UMC Location VUmc · NLErasmus MC Cancer Institute · NLEuropean Society for Blood and Marrow Transplantation · NLHeidelberg University · DEHelsinki University Hospital · FIHôpital Cardiologique du Haut-Lévêque · FRHôpital Lapeyronie · FRInstitut Paoli-Calmettes · FRKarolinska Institutet · SEOspedale Santa Maria della Misericordia di Udine · ITPoliclinico S.Orsola-Malpighi · ITPresidio Ospedaliero · ITRadboud University Nijmegen · NLRoyal Marsden Hospital · GBUniversität Hamburg · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Leipzig · DEUniversity Hospital Ulm · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: (1) allo-HSCT upfront (n=1924), (2) tandem auto-allo-HSCT (n=2004) and (3) allo-HSCT as a second line treatment and beyond (n=3405). Overall, there is a steady increase in numbers of allo-HSCT over the years. Upfront allo-HSCT use increased up to year 2000, followed by a decrease thereafter and represented 12% of allo-HSCTs performed in 2012. Tandem auto-allo-HSCT peaked around year 2004 and contributed to 19% of allo-HSCTs in 2012. Allo-HSCT as salvage after one or two or three autografts was steadily increasing over the last years and represented 69% of allo-HSCTs in 2012. Remarkable heterogeneity in using allo-HSCT was observed among the different European countries. The 5-year survival probabilities from time of allo-HSCT for the three groups after year 2004 were 42%, 54% and 32%, respectively. These results show that the use of allo-HSCT is increasing in Europe, especially as second line treatment and beyond. There is an unmet need for well-designed prospective studies investigating allo-HSCT as salvage therapy for MM.

Indexed as

AdolescentAdultAgedEuropeFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedMultiple MyelomaSurvival RateTransplantation, HomologousTreatment OutcomeYoung Adult

Identifiers

PMID27118410
OpenAlexW2397983925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.